Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study
CNB showed a relatively high and clinically useful 50% responder rate of 47.7% and an overall retention of 77.8% at 1 year. We were unable to identify specific predictors for response and retention, indicating that CNB may be beneficial for patients with a history of multiple failed ASMs, a high number of concomitant ASMs and any localisation or aetiology of focal epilepsy.
Authors
- Kerstin Alexandra Klotz (ORCID: https://orcid.org/0000-0002-1601-5384)
- Bernadette Gaida (ORCID: https://orcid.org/0000-0002-3532-6874)
- Catrin Mann (ORCID: https://orcid.org/0000-0001-6663-2631)
- Leena Kämppi (ORCID: https://orcid.org/0000-0001-5084-2159)
- Felix von Podewils (ORCID: https://orcid.org/0000-0002-3134-8697)
- Ilka Immisch
- Susanne Knake (ORCID: https://orcid.org/0000-0002-6298-0513)
- Susanne Schubert‐Bast (ORCID: https://orcid.org/0000-0003-1545-7364)
- Andreas Brunklaus (ORCID: https://orcid.org/0000-0002-7728-6903)
- Hajo M. Hamer (ORCID: https://orcid.org/0000-0003-1709-8617)
- Felix Rosenow (ORCID: https://orcid.org/0000-0002-3989-7471)
- Laurent M. Willems (ORCID: https://orcid.org/0000-0001-8226-1674)
- Johann Philipp Zöllner (ORCID: https://orcid.org/0000-0002-7245-2562)
- Adam Strzelczyk (ORCID: https://orcid.org/0000-0001-6288-9915)
- Jeanne Cuny
- Nico Melzer (ORCID: https://orcid.org/0000-0002-2420-701X)
- Gerhard Kurlemann
- Elisa Buhleier
- David Bellaire
Institutions
- Goethe University Frankfurt (DE)
- University of Helsinki (FI)
- University of Freiburg (DE)
- Philipps University of Marburg (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsmedizin Greifswald (DE)
- University Hospital Bonn (DE)
- Helsinki University Hospital (FI)
- Royal Hospital for Children (GB)
- University Medical Center Freiburg (DE)
- Universitätsklinikum Erlangen (DE)
- Düsseldorf University Hospital (DE)
- University Hospital Frankfurt (DE)
- St. Bonifatius Hospital (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Glasgow (GB)
Publication Details
- Journal
- CNS Drugs
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1007/s40263-025-01158-8
- Citations
- 12
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 17.65
Funders
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Danone
- Jazz Pharmaceuticals
- Zogenix
- GW Pharmaceuticals
- Fresenius Medical Care North America
- European Commission
- Bayer HealthCare
- Bundesministerium für Bildung und Forschung
- Suomen Kulttuurirahasto
- Eisai
- Angelini Pharma
- Servier
- Swedish Orphan Biovitrum
- Neuraxpharm
- Desitin Arzneimittel
- Novartis Pharma
- UCB Pharma